Get the Stockscreener App
43.85
0.99%
0.43
Pre-market:
44.80
0.95
+2.17%
Omnicell Inc stock is traded at $43.85, with a volume of 258.38K.
It is up +0.99% in the last 24 hours and down -3.24% over the past month.
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
See More
Previous Close:
$43.42
Open:
$43.06
24h Volume:
258.38K
Relative Volume:
0.50
Market Cap:
$2.02B
Revenue:
$1.08B
Net Income/Loss:
$-20.76M
P/E Ratio:
-95.33
EPS:
-0.46
Net Cash Flow:
$151.63M
1W Performance:
-2.32%
1M Performance:
-3.24%
6M Performance:
+11.81%
1Y Performance:
+36.86%
1-Day Range:
$42.33
$43.98
1-Week Range:
$42.33
$45.87
52-Week Range:
$25.12
$55.74
Omnicell Inc Stock (OMCL) Company Profile
Name
Omnicell Inc
Sector
Industry
Phone
(877) 415-9990
Address
4220 NORTH FREEWAY, FORT WORTH
Compare OMCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMCL
Omnicell Inc
|
43.85 | 2.02B | 1.08B | -20.76M | 151.63M | -0.46 |
|
VEEV
Veeva Systems Inc
|
233.38 | 37.89B | 2.66B | 665.91M | 1.08B | 4.05 |
|
SOLV
Solventum Corp
|
74.61 | 12.89B | 8.26B | 66.00M | 1.17B | 0.3682 |
|
DOCS
Doximity Inc
|
58.75 | 10.97B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
61.85 | 9.74B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
111.97 | 9.70B | 1.15B | 96.70M | -161.99M | 1.09 |
Omnicell Inc Stock (OMCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-03-24 | Initiated | Barclays | Underweight |
| Nov-03-23 | Downgrade | BTIG Research | Buy → Neutral |
| Nov-03-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Oct-11-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Sep-26-23 | Reiterated | Wells Fargo | Underweight |
| Aug-02-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-23 | Downgrade | Wells Fargo | Overweight → Underweight |
| Feb-27-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-03-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-09-22 | Initiated | BofA Securities | Buy |
| Jul-15-22 | Initiated | SVB Leerink | Mkt Perform |
| Dec-06-21 | Resumed | Wells Fargo | Overweight |
| Jun-09-21 | Initiated | JP Morgan | Neutral |
| May-24-21 | Initiated | BTIG Research | Buy |
| Feb-02-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-20 | Initiated | Berenberg | Buy |
| Dec-03-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-20 | Initiated | Stephens | Overweight |
| Feb-07-20 | Reiterated | Dougherty & Company | Buy |
| Nov-21-19 | Reiterated | Dougherty & Company | Buy |
| Jul-26-19 | Upgrade | Craig Hallum | Hold → Buy |
| Mar-07-19 | Reiterated | Dougherty & Company | Buy |
| Jun-29-18 | Resumed | The Benchmark Company | Buy |
| Sep-05-17 | Reiterated | The Benchmark Company | Buy |
| Jul-28-17 | Reiterated | Dougherty & Company | Buy |
| Apr-21-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-19-17 | Initiated | Dougherty & Company | Buy |
| Dec-06-16 | Reiterated | The Benchmark Company | Buy |
| Jul-07-16 | Reiterated | FBR Capital | Outperform |
| Mar-21-16 | Reiterated | Topeka Capital Markets | Buy |
| Jan-07-16 | Initiated | The Benchmark Company | Buy |
| Nov-16-15 | Reiterated | Topeka Capital Markets | Buy |
| Oct-30-15 | Reiterated | FBR Capital | Outperform |
| Sep-28-15 | Upgrade | Sidoti | Neutral → Buy |
| Jul-31-15 | Reiterated | Topeka Capital Markets | Buy |
View All
Omnicell Inc Stock (OMCL) Latest News
Assessing Omnicell: Insights From 4 Financial Analysts - Benzinga
Medicine Compounding Robot Market Booming Trends: Future - openPR
Zacks Research Has Bullish Estimate for Omnicell Q1 Earnings - MarketBeat
What is Zacks Research's Forecast for Omnicell Q2 Earnings? - MarketBeat
Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down - MSN
U.S. Pharmacy Automation Devices Market May Set Epic Growth Story | Yuyama, Baxter, Omnicell - openPR
SteelPeak Wealth LLC Invests $635,000 in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Is Omnicell Stock a Solid Pick for Your Portfolio Right Now? - MSN
Owensboro Health to Deploy Omnicell’s Technology-Enabled Services to Improve Safety and Efficiency in Medication Management - Marketscreener.com
Global Surgery Center Software Market Size, Share and Forecast - openPR
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate - Simply Wall St
How to Take Advantage of moves in (OMCL) - Stock Traders Daily
SG Americas Securities LLC Acquires 14,202 Shares of Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Exchange Traded Concepts LLC Grows Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Zacks Industry Outlook Enovis, Omnicell and Phreesia - Zacks Investment Research
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects - Yahoo Finance
The Zacks Analyst Blog Doximity, Omnicell, Embecta, Cencora and EDOC - Yahoo Finance
Omnicell, Inc. (NASDAQ:OMCL) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Assenagon Asset Management S.A. Cuts Holdings in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Automated Dispensing Machines Market 2024-2031: Global - openPR
Arkadios Wealth Advisors Boosts Position in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Where are the Opportunities in (OMCL) - Stock Traders Daily
Pharmacy Automation Market Size Trends, Regional Dynamics, and Emerging Growth Factors in Key Industries Leading to 2027 - Barchart
Pharmacy Automation Market Generated Opportunities, Future Scope (2024-2031) | Swisslog Healthcare, Omnicell, Inc. - openPR
Omnicell Sets Q4 and Full Year 2024 Earnings Release Date for February 6 - StockTitan
Wells Fargo & Company Cuts Omnicell (NASDAQ:OMCL) Price Target to $40.00 - MarketBeat
Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025 - Business Wire
Omnicell (OMCL) Introduces Central Med Automation Service - MSN
Pharmacy Automation Market Top Companies Study - openPR
United States Pharmacy Management System Market May See a Big Move | Omnicell, McKesson, GE Healthcare - openPR
Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Omnicell to Present at JP Morgan's Influential Healthcare Conference in January 2025 - StockTitan
Omnicell Gains 26.2% in a Year: What's Driving the Stock? - MSN
Central Fill Pharmacy Automation Market Detailed In New - openPR
Bank of America Cuts Omnicell (NASDAQ:OMCL) Price Target to $46.00 - MarketBeat
Research Analysts Set Expectations for Omnicell Q4 Earnings - MarketBeat
The past three years for Omnicell (NASDAQ:OMCL) investors has not been profitable - Simply Wall St
Pharmacy Automation Market Size, Growth Status to 2033 TOSHO, Takazono, ScriptPro, BD, Baxter, Omnicell - openPR
Principal Financial Group Inc. Cuts Position in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
Analysts Set Omnicell, Inc. (NASDAQ:OMCL) Target Price at $52.00 - MarketBeat
Omnicell (NASDAQ:OMCL) Trading Down 2.4%What's Next? - MarketBeat
Omnicell (NASDAQ:OMCL) Shares Pass Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Jane Street Group LLC Has $2.20 Million Stock Holdings in Omnicell, Inc. (NASDAQ:OMCL) - MarketBeat
The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories - Zacks Investment Research
4 Healthcare Technology Innovators to Invest in Before the New Year - Zacks Investment Research
Why Omnicell (OMCL) Might be Well Poised for a Surge - MSN
Medication Management Market (2024-2032): Industry Insights, - openPR
Omnicell's SWOT analysis: healthcare tech firm's stock faces growth hurdles By Investing.com - Investing.com Australia
Omnicell's SWOT analysis: healthcare tech firm's stock faces growth hurdles - Investing.com
Omnicell Inc Stock (OMCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):